welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (PolarisDMD)

key information

study id #: NCT03703882

condition: Muscular Dystrophy, Duchenne

status: recruiting


The PolarisDMD study is a Phase 3, global study to evaluate the efficacy and safety of edasalonexent in pediatric patients with a genetically confirmed diagnosis of DMD. Male patients from 4-7 years of age (up to 8th birthday) will be enrolled.

Edasalonexent is an orally administered small molecule that inhibits NF-kB, which is the key link between loss of dystrophin and disease pathology and plays a fundamental role in the initiation and progression of skeletal and cardiac muscle disease in DMD.

intervention: Edasalonexent, Placebo

mechanism of action: NF-KB inhibitor to prevent muscle damage and promote muscle regeneration

results: https://clinicaltrials.gov/ct2/show/results/NCT03703882

last updated: July 19, 2019

study details

start date: October 2, 2018

estimated completion: June 2020

phase of development: Phase 3

size / enrollment: 125

study description:
The study includes a 52-week, randomized, double-blind, placebo-controlled period, followed by a 2-week follow- up. Approximately 125 boys with DMD will be enrolled in this trial, with 2 boys receiving edasalonexent for every 1 boy receiving placebo.
Following completion of the treatment period, patients may elect to continue in a separate open-label extension study.

primary outcomes:

  • Change from baseline in North Star Ambulatory Assessment (NSAA) [Time Frame: 52 Weeks]

secondary outcomes:

  • Safety and tolerability measured by number of treatment- emergent adverse events (TEAEs) and serious adverse events (SAEs) [Time Frame: 52 Weeks]
  • Change from baseline in 10-meter walk/run test [Time Frame: 52 Weeks]
  • Change from baseline in time to stand from supine [Time Frame: 52 Weeks]
  • Change from baseline in 4-stair climb [Time Frame: 52 Weeks]

inclusion criteria:
• Written consent/assent by patient and/or legal guardian as per regional and/or Institutional Review Board (IRB)/Independent Ethics Committee (IEC) requirements
• Diagnosis of DMD based on a clinical phenotype with increased serum creatine kinase (CK) and documentation of mutation(s) in the dystrophin gene known to be associated with a DMD phenotype
• Able to perform stand from supine without assistance in =< 10 seconds
• Able to perform the 10MWT and 4-stair climb
• Followed by a doctor or medical professional who coordinates Duchenne care on a regular basis and willingness to disclose patient's study participation with medical professionals

exclusion criteria:
• Use of corticosteroids within 24 weeks prior to Day 1; use of inhaled, intranasal, and topical corticosteroids is permitted
• Use of another investigational drug, idebenone, or dystrophin-focused therapy within 4 weeks. Exception: Patients who have received at least 24 weeks of a stable dose of eteplirsen prior to Day 1, and expected to continue treatment, will be eligible
• Use of the following within 4 weeks prior to Day 1: immunosuppressive therapy, warfarin, phenytoin, S mephenytoin, cyclosporine, dihydroergotamine, ergotamine, fentanyl, alfentanil, pimozide, quinidine, sirolimus, tacrolimus, or paclitaxel
• Use of human growth hormone within 3 months prior to Day 1
• Other prior or ongoing significant medical conditions

study contacts

sponsor: Catabasis Pharmaceuticals

contacts: Maria C Mancini, Vice President, Clinical Operations; 617-349-1971; DMDtrials@catabasis.com

investigators: Joanne M Donovan, Chief Medical Officer, MD, PhD; Catabasis Pharmaceuticals

locations: United States, Australia, Canada, Germany, Ireland, Israel, Sweden, United Kingdom